Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Buspirone · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BUSPAR® 30 mg Tablet | DRUG | 1 x 30 mg, single-dose fed |
| Buspirone Hydrochloride 30 mg Tablet | DRUG | 1 x 30 mg, single-dose fed |
Inclusion Criteria: * Screening Demographics: All volunteers selected for this study will be healthy men or women 18 years of age or older at the time of dosing. The volunteer's body mass index (BMI) is less than or equal to 30. * Screening Procedures: Each volunteer will complete the screening pro...
Buspirone is a small molecule drug developed by Teva Pharmaceutical Industries Limited under the ticker TEVA. It is also known as Buspirone Hydrochloride 30 mg Tablet. The drug is currently in Phase 1 clinical development, with two completed trials involving healthy volunteers.
Buspirone targets the HTR1A receptor, also known as the serotonin 1A receptor. It acts as a partial agonist at this target. This mechanism is specific to the drug's molecular action as a small molecule.
Buspirone is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker symbol TEVA. Teva is the company responsible for the clinical development of this drug asset.
Buspirone is in Phase 1 clinical development. It has completed two Phase 1 trials and is not currently approved for any indication. The trials were conducted in healthy volunteers.
Buspirone has been studied in two completed Phase 1 trials: NCT00840606, titled Buspirone Hydrochloride 30mg Tablets, Fasting, and NCT00840398, titled Buspirone Hydrochloride 30mg Tablets, Non-Fasting. Both enrolled healthy volunteers in the United States.